A Single-Blind, Randomised, Placebo-Controlled, Parallel-Group, Single Centre Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended-Release Tablets AZD0837 After Single and Repeated Oral Administration to Young Healthy Male Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 0837 (Primary)
- Indications Thromboembolism
- Focus Adverse reactions
- Sponsors AstraZeneca
- 14 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 14 Jul 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2009 New trial record